News
BLCO
14.44
+6.18%
0.84
Morgan Stanley upgrades Bausch + Lomb, cites improving margins
Morgan Stanley upgrades Bausch + Lomb, cites improving margins. Morgan Stanley raised its price target on the stock to $18 from $16. The investment bank says the company's underlying EBITDA margin is “performing considerably ahead of expectations.” Morgan Stanley sees upside risk to 2024 and 2025 growth expectations.
Seeking Alpha · 13h ago
Bausch + Lomb Corporation: A Buy Rating Amid Market Growth and Strategic Expansion
TipRanks · 16h ago
American Airlines To Rally Around 59%? Here Are 10 Top Analyst Forecasts For Monday
Wedbush raised the price target for BJ’s Restaurants, Inc. (NASDAQ:BJRI) to $43. B of A Securities cut Fox Factory Holding Corp. Price target from $55 to $48. Mizuho boosted the price targets for Robinhood Markets, Inc and Bausch + Lomb Corporation.
Benzinga · 16h ago
Morgan Stanley Upgrades Bausch & Lomb to Overweight, Raises Price Target to $18
Benzinga · 18h ago
Weekly Report: what happened at BLCO last week (0429-0503)?
Weekly Report · 19h ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bausch + Lomb Corporation (BLCO), 10x Genomics (TXG) and LivaNova (LIVN)
TipRanks · 4d ago
HC Wainwright & Co. Reiterates Buy on Bausch & Lomb, Maintains $20 Price Target
Benzinga · 4d ago
RBC Capital Issues a Buy Rating on Bausch + Lomb Corporation (BLCO)
TipRanks · 4d ago
Bausch + Lomb Corporation: Poised for Market Leadership and Robust Growth—A Buy Rating Review
TipRanks · 4d ago
Robust Start and Organic Growth Affirm Bausch + Lomb’s Buy Rating
TipRanks · 4d ago
Buy Rating Affirmed for Bausch + Lomb: Strong Q1 Performance and Promising Growth Outlook Despite FX Headwinds
TipRanks · 4d ago
Harrow: The Bull Thesis Is On Track, But Short-Term Challenges Loom
Harrow, Inc. Will miss Q1 2024 earnings estimates as a result of the Change Healthcare cyberattack. Change Healthcare is the largest clearinghouse for medical claims in the U.S. Harrow's long-term bull thesis is stronger than ever. The company is expanding into the branded pharmaceutical product market. The cyberattack has crippled reimbursement and will impact the company in 2024.
Seeking Alpha · 4d ago
Bausch + Lomb Corporation: Quarterly Report on Form 10-Q for the Quarterly Period Ended March 31, 2024
Press release · 5d ago
Needham Reiterates Hold on Bausch & Lomb
Benzinga · 5d ago
Needham Reaffirms Their Hold Rating on Bausch + Lomb Corporation (BLCO)
TipRanks · 5d ago
BLCO Stock Earnings: Bausch & Lomb Meets EPS, Misses Revenue for Q1 2024
Bausch & Lomb reported earnings per share of 7 cents for the first quarter of 2024. The company reported revenue of $1.10 billion. This was 24.21% worse than the analyst estimate for revenue. Bausch and Lomb also reported results for the second quarter of 2016.
Investorplace · 5d ago
Bausch + Lomb Reports Strong Q1 Growth
TipRanks · 5d ago
Bausch + Lomb Reports Robust Q1 2024 Growth
TipRanks · 5d ago
Wall Street Set To Open Lower After AMD Earnings Disappoint As Traders Look To Fed's Powell For Relief: Why This Analyst Sees Incoming Summer Rally
Major averages closed lower on Tuesday, snapping a two-day winning run. AMD's underwhelming quarterly report put pressure on the tech sector and the broader market. FED Chairman Jerome Powell's press conference on Wednesday could be key to the session's direction. The Fed is expected to announce an interest rate decision later in the day.
Benzinga · 5d ago
Bausch + Lomb Announces First-Quarter 2024 Results
Bausch + Lomb Corporation announces its first-quarter 2024 financial results. The company reported revenue of $1.099 billion for the first quarter of 2024, an increase of 18%. The company saw broad-based growth across all segments and key franchises, including Daily SiHy lenses, LUMIFY and eye vitamins.
Barchart · 5d ago
More
Webull provides a variety of real-time BLCO stock news. You can receive the latest news about Bausch + Lomb Corporation through multiple platforms. This information may help you make smarter investment decisions.
About BLCO
Bausch + Lomb Corporation is a Canada-based global eye health company. The Company’s Vision Care segment includes both a contact lens business and a consumer eye care business that consists of contact lens care products, over the counter (OTC) eye drops and eye vitamins. The Company’s Ophthalmic Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Its Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. The Company’s brands include PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, and many more.